Jenneke Leentjens, Saskia Middeldorp, and colleagues, published a review on the current knowledge of COVID-19 associated coagulopathy and the role of antithrombotic therapies in the Lancet Haematology.
COVID-19 is associated with a high incidence of thrombotic complications, which can be explained by the complex and unique interplay between coronaviruses and endothelial cells, the local and systemic inflammatory response, and the coagulation system. Empirically, often an intensified dose of pharmacological thrombosis prophylaxis is being used in patients admitted to hospital with COVID-19. Several guidelines on this topic have been published, with varying and weak recommendations as a result of the lack of high quality and direct evidence .
In this viewpoint they summarize the pathophysiology of COVID-19 coagulopathy in the clinical context of patients, i.e. those who are ambulant, admitted to hospital (critically ill or non-critically ill), and those post-discharge from hospital. The researchers also review data from emerging randomized controlled trials in the past year of antithrombotic therapy in COVID-19 patients, and they focus on the unique international collaboration in large platform trials that have yielded the first high quality data that guide clinicians to optimize anticoagulant prophylaxis and to treat COVID-associated coagulopathy. The first-ever trial in non-critically ill patients who were admitted to hospital has shown that a therapeutic dose of low-molecular-weight heparin might improve clinical outcomes in this population. In critically ill patients, this same treatment does not improve outcomes and prophylactic dose thromboprophylaxis is recommended. In the upcoming months they expect numerous data from the ongoing antithrombotic COVID-19 studies to guide clinicians at different stages of the disease.
Related news items
New start-up Patholyt will bring AI research into pathology diagnostics21 September 2021
Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research.read more
Young Radboudumc researchers receive grant to engage in bio-medical and health research that is off the beaten path16 September 2021
The ZonMw Off Road program is once again giving young scientists the opportunity to conduct innovative research in medical and/or health care. This research is off the beaten track and aims to bring about new insights and unexpected breakthroughs for healthcare and healthcare innovation.read more
Infections increase risk to develop dementia16 September 2021
In a recently published study, Radboudumc researchers investigated the effects of infectious events on cognitive decline and the development of dementia and its possible structural underpinning using pre- and post-infection MRI of the brain.read more